AzTrials
AzTrials

AnesthesiaPhase 4NCT03791424

Changes of Skin Resistance After Midazolam and After the End of Anaesthesia

A Phase 4 study testing Midazolam in people with Anesthesia, run by Charles University, Czech Republic at 1 site in Czechia.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

It has been described that sympathetic activity, measured as changes in electrical skin resistance (SR), may be used to assess the adequacy of general anaesthesia. Our prospective study investigated how far measurements of skin resistance can help determine level of sedation. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Anesthesia
What is being tested?
Midazolam
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
28 participants
Where
1 siteCzechia
Study dates
1 Oct 2014to 26 Jun 2015
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • adult patients scheduled for knee arthroscopy or minor plastic surgery under general anaesthesia

Who cannot join

  • previous history of taking drugs affecting mental functions, history of psychic illness, implanted electrical device, know allergy to benzodiazepines, myasthenia gravis, ASA classification ASA 3 and more. All patients consented not to use any medication for sedation or anxiety, opioid analgesics, ethanol and illicit drugs 24 hours before surgery.

Trial locations and contacts

1 site in 1 country.

Czechia1 site
  • University Hospital Kralovske Vinohrady

    Prague, 100 00

Other trials in Czechia

About this study

It has been described that sympathetic activity, measured as changes in electrical skin resistance (SR), may be used to assess the adequacy of general anaesthesia. Our prospective study investigated how far measurements of skin resistance can help determine level of sedation. The secondary aim was to investigate if changes in skin resistance can be used for assessing recovery from anaesthesia.

Read the detailed description

Introduction Before anaesthesia, benzodiazepines are routinely used to reduce anxiety before anaesthesia and surgery. Usually anxiolysis is preferable to sedation, which may interfere with recovery after short procedures. Unfortunately, although anxiolytic sedatives are widely used in clinical practice, the methodology for assessing treatment effect of these compounds has not been well developed. Psychologic tests like the Hamilton Anxiety Rating Scale (HARS), the Wang Anxiety Rating Scale (WARS), or Zung Self-Rating Anxiety Scale (SAS) were used to assess changes in anxiety were developed for measuring effect of long-term therapy and are rather cumbersome and difficult to use in routine anaesthetic praxis.

More commonly used test in clinical perioperative use are the Ramsay sedation scale (RSS), the Richmond Agitation-Sedation Scale (RASS) and the Observer's Assessment of Alertness and Sedation scale (OAASS), but they focus mainly on level of sedation and not the level of anxiolysis. There are several reports demonstrating that there is a correlation between level of anxiety and changes in skin resistance.

Changes of skin resistance (SI) were first used in criminology in 1897 and in 1921 the method was used in criminology by August Larson together with changes of heart rate, respiratory rate and blood pressure for construction of polygraph. This method was many times validated and polygraph is still used as a "lie detector". More recently sever studies appeared demonstrating correlation between changes of skin resistance and sedation grade, bispectral index, reaction to stimulation, pain and motor activity.

The present double-blinded study was designed to refine methodology for objective evaluating effect of sedative and anxiolytic agents. The primary aim of our study was to examine if of changes in skin resistance after placebo pre-screening can be used for objective assessment of an anxiolytic effect of drugs compared to commonly used subjective scales like Ramsay sedation scale (RSS), or The Richmond Agitation-Sedation Scale (RASS) and Observer's Assessment of Alertness and Sedation scale(OAASS). The secondary aim was to evaluate if changes of skin resistance can be used for assessing recovery from anaesthesia.

Patients The study was performed in adult patients scheduled for knee arthroscopy or minor plastic surgery under general anaesthesia. Consent was obtained the day before surgery during pre-anaesthetic visit. Exclusion criteria were previous history of taking drugs affecting mental functions, history of psychic illness, implanted electrical device, know allergy to benzodiazepines, myasthenia gravis, ASA classification ASA 3 and more. All patients consented not to use any medication for sedation or anxiety, opioid analgesics, ethanol and illicit drugs 24 hours before surgery. Patients were instructed that they will be administered by a random order first sedative agent or placebo and will be observed for their level of sedation.

Measurements After arrival at the operating theatre, and venepuncture two standard AgCl ECG electrodes (Medico Electrodes International ltd.) size 32 mm x 52 mm (27x35) were attached to the palm side of the second and third finger of the non-dominating hand. Multimeter DM 3900 (Mastech) was used for measurements of SR. The device was controlled and approved for use in humans by the Department of Medical Biophysics and Informatics of the 3rd Medical Faculty of Charles University.

Observer's Assessment of Alertness and Sedation (OAAS) scale was used as a standard tool for measurements of sedation level at the same intervals as measurements of SR. The person providing OAAS assessment was blinded to the order of midazolam and placebo injection and only the anaesthetist administering both injections knew the order of drugs.

Data recording Ten min. rest break was given to participants in order that they adapt to the test situation. The rest value of SR was noticed and next all patients were administered placebo first and after 5 min period midazolam 2 mg i.v. After next 5 minutes patients were administered standard general anaesthesia with propofol, oxygen, nitrous oxide 60 % and isoflurane 1 MAC via laryngeal mask and sufentanil as needed. Monitoring was standard for this type of surgery (ECG, non-invasive blood pressure - NIBP, capnography and pulse oximetry). SR and OASS were recorded again after stop of volatile anaesthetic agent till opening eyes of the patient and obtaining verbal contact.

Statistical analysis SR values before placebo administration, 5 minutes after placebo, 5 minutes after midazolam, 5 min. after induction, at the end of surgery, 0 isoflurane level after anaesthesia with closed eyes and after eyes opening were recorded. Changes in SR values compared to baseline data were used for analyses by paired t-test. These relative changes enabled to compare only the course of changes independently of different absolute values. Pearson´s correlation coefficients were used to analyse relationship between OASS and SR values. P-value < 0.05 was considered statistically significant.

The primary aim of our study was to assess if SR can be used as an objective measurement of level of sedation compared to much or less subjective OAAS. OASS was chosen because scoring was originally introduced to assess sedation with benzodiazepines, which was used in our study, too. The categories were responsiveness, speech, facial expression and eye appearance and each category was originally scored in 5 dimensions. The OAAS scale was found to have a high discriminatory power for the different levels of sedation (3), but may vary between observers. There is a limited number of methods for assessment onset and intensity of sedation. Commonly used Bispectral Index Score (BIS) monitoring is not dependent on a person and is used mainly during general anaesthesia. On the other hand the authors of a large meta-analysis concluded that its use for sedation in largely unreliable.

Conditions
Anesthesia
Being tested
Midazolam
Keywords
sedation, midazolam, skin resistance, measurements

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • MidazolamDrug

    Also called Sedation

    Administering premedication with sedative drug to relieve anxiety

Study groups in NCT03791424
Study groupRoleWhat they receive
MidazolamExperimentalMidazolam 2 mg was administered 5 min. after placebo and 5 min. before inducton to general anaesthesia IV.
Receives: Drug: Midazolam
ControlPlacebo comparatorNormal saline 5 ml was administered 10 min. after insertion of intravenous cannula IV..
Receives: Drug: Midazolam

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Changes of skin resistence (percent from base-line values measured in ohms) during sedation

    Investigation how far measurements of skin resistance can help determine level of sedation induced by intravenous midazolam

    Measured: 10 min. before administration and 5 min. after administration of midazolam (total 15 min.)

Secondary outcomes (1)
  1. Changes of skin resistence (percent from base-line values and values before termination of inhalational agent administration measured in ohms) during recovery from anaesthesia

    Investigation how far measurements of skin resistance can help determine level of recovery from general anaesthesia

    Measured: From termination of inhalational agent administration till recovery to verbal comunication (expected time max. 15 min)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Jan 2019
  2. Study start1 Oct 2014
  3. Primary completion26 Jun 2015
  4. Study completion26 Jun 2015

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Diagnosis
Allocation
Non-randomised
Intervention model
Crossover
Model description
Multimeter DM 3900 was used for measurements of SR. The device was approved for use in humans by the Department of Medical Biophysics and Informatics of the 3rd Medical Faculty of Charles University. Observer's Assessment of Alertness and Sedation scale was used as a standard tool for measurements of sedation level at the same intervals as measurements of SR. 10 min. rest break was given to participants in order that they adapt to the test situation. The rest value of SR was noticed and next all patients were administered placebo first and after 5 min period midazolam 2 mg i.v. After next 5 minutes patients were administered standard general anaesthesia with propofol, oxygen, nitrous oxide 60 % and isoflurane 1 MAC via laryngeal mask and sufentanil as needed. Changes in skin resistance were measured again immediately after stop of volatile anaesthetics till eye opening and verbal contact.
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
28 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03791424
Sponsor's protocol ID
Oxytocin01
Status last verified
Dec 2018
First submitted
17 Sep 2018
Last updated
3 Jan 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Midazolam in people with Anesthesia, run by Charles University, Czech Republic at 1 site in Czechia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 3 Jan 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Czechia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Changes of skin resistence (percent from base-line values measured in ohms) during sedation (time frame: 10 min. before administration and 5 min. after administration of midazolam (total 15 min.)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Jan 2019; AzTrials last refreshed its copy on 8 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in